Veracyte
Veracyte is a global leader in molecular diagnostics, dedicated to transforming cancer care through innovative genomic tests. They develop and commercialize tests that help clinicians make informed treatment decisions, improve patient outcomes, and advance scientific understanding. Their portfolio includes tests for thyroid, prostate, bladder, and breast cancers, among others. Veracyte's approach combines advanced genomic technology, AI-assisted data mining, and evidence generation to support personalized medicine and global access to diagnostics.
Industries
Nr. of Employees
large (251-1000)
Veracyte
South San Francisco, California, United States, North America
Products
Genomic sequencing classifier for thyroid nodule assessment
Whole-transcriptome RNA sequencing–based classifier performed on fine needle aspiration samples to distinguish benign from suspicious thyroid nodules and provide mutation insights to guide treatment decisions.
Prostate cancer gene expression classifier
A 22-gene expression assay applied to prostate biopsy or surgical tissue to predict risk of metastasis and guide treatment intensity decisions.
Bladder tumor molecular subtyping classifier
Whole-transcriptome–based assay that profiles ~219 genes and classifies bladder tumors into molecular subtypes (luminal vs non-luminal subtypes) to inform risk of upstaging and potential benefit from neoadjuvant chemotherapy.
Breast cancer prognostic gene signature assay (PAM50-based)
Assay that measures the PAM50 gene signature combined with clinical factors to provide a 10-year recurrence risk score and molecular subtype classification for HR+/HER2- early-stage breast cancer.
FFPE RNA extraction kit
Kit and instructions for extraction of RNA from formalin-fixed, paraffin-embedded (FFPE) tissue to prepare samples for downstream transcriptomic assays.
Genomic sequencing classifier for thyroid nodule assessment
Whole-transcriptome RNA sequencing–based classifier performed on fine needle aspiration samples to distinguish benign from suspicious thyroid nodules and provide mutation insights to guide treatment decisions.
Prostate cancer gene expression classifier
A 22-gene expression assay applied to prostate biopsy or surgical tissue to predict risk of metastasis and guide treatment intensity decisions.
Bladder tumor molecular subtyping classifier
Whole-transcriptome–based assay that profiles ~219 genes and classifies bladder tumors into molecular subtypes (luminal vs non-luminal subtypes) to inform risk of upstaging and potential benefit from neoadjuvant chemotherapy.
Breast cancer prognostic gene signature assay (PAM50-based)
Assay that measures the PAM50 gene signature combined with clinical factors to provide a 10-year recurrence risk score and molecular subtype classification for HR+/HER2- early-stage breast cancer.
FFPE RNA extraction kit
Kit and instructions for extraction of RNA from formalin-fixed, paraffin-embedded (FFPE) tissue to prepare samples for downstream transcriptomic assays.
Services
Centralized CLIA laboratory testing services
Provision of clinical sequencing and gene-expression testing performed in CLIA-certified centralized laboratories, with reporting to ordering clinicians.
IVD development and distribution for local laboratories
Development of assays as in vitro diagnostics for use by local labs and hospitals outside the US, including regulatory and market access support.
Clinical evidence generation and research collaboration
Support for clinical validation studies, publication efforts, and collaborative research using amassed genomic datasets.
Reimbursement and payer support services
In-house claims processing and payer engagement to obtain coverage policies and optimize reimbursement for genomic tests.
Bioinformatics and data analytics support
Development and deployment of bioinformatics pipelines, data management systems and analytic tools to support test interpretation and research.
Centralized CLIA laboratory testing services
Provision of clinical sequencing and gene-expression testing performed in CLIA-certified centralized laboratories, with reporting to ordering clinicians.
IVD development and distribution for local laboratories
Development of assays as in vitro diagnostics for use by local labs and hospitals outside the US, including regulatory and market access support.
Clinical evidence generation and research collaboration
Support for clinical validation studies, publication efforts, and collaborative research using amassed genomic datasets.
Reimbursement and payer support services
In-house claims processing and payer engagement to obtain coverage policies and optimize reimbursement for genomic tests.
Bioinformatics and data analytics support
Development and deployment of bioinformatics pipelines, data management systems and analytic tools to support test interpretation and research.
Expertise Areas
- Cancer genomic diagnostics
- Molecular subtyping and prognostic assays
- Bioinformatics and machine learning for genomics
- Clinical evidence generation and validation
Key Technologies
- Whole-transcriptome RNA sequencing
- Gene expression profiling (targeted and panel-based)
- Machine learning for genomic classification
- Whole-genome sequencing for MRD detection